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Abstract
Objectives To compare the PanCan model, Lung-RADS and
the 1.2016 National Comprehensive Cancer Network
(NCCN) guidelines for discriminating malignant from benign
pulmonary nodules on baseline screening CT scans and the
impact d iameter measurement methods have on
performances.
Methods From the Danish Lung Cancer Screening Trial data-
base, 64 CTs with malignant nodules and 549 baseline CTs
with benign nodules were included. Performance of the sys-
tems was evaluated applying the system's original diameter
definitions: Dlongest-C (PanCan), DmeanAxial (NCCN), both ob-
tained from axial sections, and Dmean3D (Lung-RADS).
Subsequently all diameter definitions were applied uniformly
to all systems. Areas under the ROC curves (AUC) were used
to evaluate risk discrimination.
Results PanCan performed superiorly to Lung-RADS and
NCCN (AUC 0.874 vs. 0.813, p = 0.003; 0.874 vs. 0.836,
p = 0.010), using the original diameter specifications. When
uniformly applying Dlongest-C, Dmean3D and DmeanAxial,
PanCan remained superior to Lung-RADS (p < 0.001 – p =
0.001) and NCCN (p < 0.001 – p = 0.016). Diameter definition
significantly influenced NCCN’s performance with Dlongest-C
being the worst (Dlongest-C vs. Dmean3D, p = 0.005; Dlongest-C
vs. DmeanAxial, p = 0.016).
Conclusions Without follow-up information, the PanCan
model performs significantly superiorly to Lung-RADS and
the 1.2016 NCCN guidelines for discriminating benign from
malignant nodules. The NCCN guidelines are most sensitive
to nodule size definition.
Key Points
• PanCan model outperforms Lung-RADS and 1.2016 NCCN
guidelines in identifying malignant pulmonary nodules.
• Nodule size definition had no significant impact on Lung-
RADS and PanCan model.
• 1.2016 NCCN guidelines were significantly superior when
using mean diameter to longest diameter.
• Longest diameter achieved lowest performance for all
models.
• Mean diameter performed equivalently when derived from
axial sections and from volumetry.
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Computer tomography . Solitary pulmonary nodule . Risk
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Dlongest-M Longest diameter on axial sections, derived from
manual measurements
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Mean diameter based on volumetric information,
derived from computerized semi-automated
segmentations
DmeanAxial Mean of longest and perpendicular diameter on
axial sections, derived from computerized semi-
automated segmentations
LDCT Low-dose computed tomography
NCCN National Comprehensive Cancer Network
NELSON Dutch-Belgian Lung Screening Trial
PanCan Pan-Canadian Early Detection of Lung Cancer
Study
ROC Receiver operating characteristic
Introduction
The cost-effectiveness of a lung cancer screening programme
is influenced by the lung nodule management protocol [1].
Differentiating high-risk nodules from low-risk nodules based
on nodule characteristics remains a difficult task [2, 3]. To aid
radiologists in recommending the most appropriate follow-up
procedure, several categorical management protocols and
scoring systems have been published recently. In 2014, the
American College of Radiology (ACR) published version
1.0 of the Lung-RADS Assessment Categories to standardize
the CT lung screening reporting and management recommen-
dations [4]. Both Lung-RADS and the 1.2016 National
Comprehensive Cancer Network (NCCN) base their nodule
management on nodule type, size and nodule growth over
time [5]. Their category definitions and associated manage-
ment recommendations have been determined empirically
based on previous publications and clinical experience,
resulting in slight variations across systems.
In 2013, the PanCan prediction models were published [6],
estimating the probability of cancer in pulmonary nodules
detected on first-screening CT scans. The parameters of these
models were mathematically derived based on screening data.
In addition to nodule-related aspects such as size, type or
location, they take subject characteristics into account to com-
pute a nodule risk index on a continuous scale. Validation of
these models was performed using data from chemopreven-
tion trials of the British Columbia Cancer Agency (BCCA)
[6], and independently of that using the Danish Lung Cancer
Screening Trial (DLCST) [7], revealing areas under the re-
ceiver operating characteristic (ROC) curve (AUC) ranging
from 0.940 for the first to 0.834 for the latter.
The nodule management strategy has a large impact on
screening programmes, especially when large databases need
to be analysed. Since it remains unclear which approach
works best to determine the subgroup of screen-detected nod-
ules that require more intense work-up, we were interested in
the performance differences between these three strategies.
The purpose of this study was to compare the performance
of the PanCan model, Lung-RADS and the 1.2016 NCCN
guidelines to differentiate the same set of malignant from be-
nign screen-detected pulmonary nodules and to determine the
impact of different diameter measurement methods on the
model’s performances.
Methods
Materials
All study cases in this retrospective study were derived from
the DLCST. Details regarding the DLCST protocol have been
reported previously [8]. Approval by the DLCST ethics com-
mittee as well as informed consent from all participants were
received.
Data selection
We considered nodules annotated by at least one of the two
screening radiologists. From the baseline annotations, two
groups were defined: (i) nodules that were found to be cancer
and (ii) nodules considered benign within the follow-up of
approximately 9 years. In total, 70 primary lung cancers were
found in 64 participants. For the malignant nodules, the scan
on which the malignant nodule was annotated for the first time
by at least one screening radiologist was included in the study.
As a consequence, for 29 cancers in 27 participants, the scan
included in this study did not represent the baseline CT (T0)
scan. For eight of these participants the T0 scans with anno-
tated benign nodules were excluded, in order to have only one
CT scan input per participant. All other benign nodules anno-
tated at T0 by a screening radiologist were included. In total,
the dataset consisted of 930 nodules in 613 participants: 70
malignant nodules in 64 participants and 860 benign nodules
in 549 participants.
CTacquisition
All CT scans were performed using a multi-detector CT scan-
ner (16-row Philips Mx 8000, Philips Medical Systems,
Eindhoven, The Netherlands), with a low-dose protocol of
120 kV and 40 mAs, and reconstructed in thin sections
(1 mm) [8].
Quantitative nodule assessment
All nodules were semi-automatically segmented to as-
sess the longest and perpendicular diameter on axial
sections, the mean diameter based on volumetric infor-
mation of the total nodule and, if present, of the solid
component (CIRRUS Observer, Diagnostic Image
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An a l y s i s G r o u p , R a d b o u dUMC , N i jm e g e n ,
The Netherlands). The mean diameter based on
volumetry refers to the diameter of a sphere that is
adapted as close as possible to the nodule extension in
all three dimensions.
PanCan prediction model
We used the full model including spiculation (2b),
which will be referred to as the PanCan model through-
out the text to calculate the nodule risk index on a
continuous scale for each nodule [6]. The PanCan mod-
el considers the parameters age, sex, family history of
lung cancer, emphysema, nodule size, nodule type, nod-
ule location, additional nodule count per scan and spic-
ulation. Based on the study by McWilliams et al. [6],
the longest diameter on axial sections was used as the
definition of nodule size, derived from computerized
semi-automated volumetric segmentations (Dlongest-C).
Manually measured diameters were also available from
the DLCST database (Dlongest-M). The parameters nodule
type (solid, part-solid, pure ground-glass or perifissural
nodule (PFN)), presence of emphysema, spiculation and
nodule calcification were scored according to the
PanCan model definitions by an experienced radiologist
(E.Th.S), who was involved in the readings of the
NELSON trial [9]. All other parameters were available
from the DLCST database. Completely calcified and
perifissural nodules were excluded in the PanCan model
and therefore given a nodule risk index of 0% in our
study. Although the PanCan model outcome uses a con-
tinuous scale in the range of 0–100%, cut-off points of
the PanCan model's nodule risk index have been pub-
lished to serve as a framework to guide clinical inves-
tigators, consisting of four categories [10].
Lung-RADS assessment categories
Lung-RADS consists of five categories, which are based
on nodule type, size and growth. Since we did not in-
clude follow-up information, we did not consider
growth in our study. In the original publication, nodule
size was defined as the average diameter, rounded to
the nearest whole number. We therefore used the 3D
mean diameter derived from semi-automated volumetric
segmentations (Dmean3D). All nodules were assigned to
one of the categories as proposed by the ACR [4].
National Comprehensive Cancer Network guidelines
The NCCN developed guidelines for management of
screen-detected pulmonary nodules, based on nodule
type, size and nodule growth. Nodule size was defined
in the guidelines as the mean of the longest diameter
and the perpendicular diameter on axial sections
(DmeanAxial). In this study we used the NCCN guidelines
published in 2015 (version 1.2016). All nodules in our
study were assigned to one of six categories as pro-
posed by the guidelines [5].
The criteria for the categories of the scoring systems de-
scribed above are specified in Table 1.
Statistical analysis
Per participant, the nodule with the highest nodule risk
index or category (risk-dominant nodule) was determined
for the two categorical scoring systems and the PanCan
model independently. Subsequently, based on the individ-
ual performance of the scoring system, different nodules
could be determined as being the risk-dominant nodule
for the three systems. In participants with multiple risk-
dominant nodules for a scoring system, only one risk-
dominant nodule was randomly selected per system. A
ROC analysis was performed to determine the discrimi-
native power of the PanCan model, Lung-RADS and the
1.2016 NCCN guidelines. Because no follow-up infor-
mation was included, our analysis is confined to how
well PanCan model category 4, Lung-RADS category
4A and 4B, and the 1.2016 NCCN guidelines category
6 predict malignancy. AUC values served as indicators of
performance and were calculated for all three scoring
systems using MedCalc software package (MedCalc ver-
sion 16.4.3, https://www.medcalc.org).
To assess differences between the three systems, first
the performances were determined applying the system's
individual nodule size definition as stated in the
publications.
For the PanCan model calculations were done twice: using
the manually measured longest diameter available from the
DLCST database (Dlongest-M) and using the longest diameter
derived from the computerized semi-automatic software seg-
mentations (Dlongest-C).
To assess the susceptibility of the systems to nodule size
definition, performances were subsequently determined by
applying uniformly the same nodule size definition (Dlongest-
C, Dmean3D and DmeanAxial, respectively).
Performances were compared pairewise using the DeLong
method [11]. Bonferroni correction was applied for the com-
parison between the three systems, resulting in a statistically
significant difference at p <0.017.
Differences in dataset characteristics were compared using
chi-square analysis for categorical data and unpaired t-test
analysis for continuous data in SPSS 20.0 (SPSS Inc.,
Chicago, IL, USA). Statistically significant differences were
defined at p <0.05.
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Results
For 497 participants (497/613, 81%), the three systems
identified the same nodule as risk-dominant. In 116 par-
ticipants (116/613, 19%), the three systems identified dif-
ferent risk-dominant nodules. Figure 1 illustrates nodules
considered as being risk-dominant by all systems, while
Fig. 2 shows an example of three nodules identified as the
risk-dominant nodule by the three systems in a single
participant. Figure 3 illustrates examples of nodules where
the risk estimation depended on the applied nodule size
definition.
Table 2 shows the demographics of the included par-
ticipants and risk-dominant nodules. Statistically signifi-
cant differences between the malignant and benign nod-
ules were seen for nodule size (Dlongest-C, Dmean3D and
DmeanAxial, all p <0.001), nodule type (p <0.001),
perifissural nodule type (p = 0.017), the presence of
spiculation (p <0.001), calcification (p = 0.001) or fam-
ily history of lung cancer (p = 0.043) and nodule count
(p = 0.017). The median time between the CT scan used
in this study and the date of lung cancer diagnosis was
13.9 months (range 0.3–84.8 months , average
23.2 months)
Performance of the three scoring systems
Using the nodule size definitions as described in the original
publications, the PanCan model performed best (AUC 0.874,
using Dlongest-C), followed by the NCCN guidelines (0.836)
and Lung-RADS (0.813). Statistically significant differences
occurred between PanCan and Lung-RADS (p = 0.003) and
between PanCan and the NCCN guidelines (p = 0.010).
The PanCan model yielded a lower performance when
using Dlongest-M (0.869 vs. 0.874; p = 0.586); the difference
was not statistically significant. Results are summarized in
Table 3 and Fig. 4A.
Impact of nodule size definition on performance per
system
All systems yielded the highest AUC-values when using
Dmean3D for nodule size, followed by DmeanAxial, and the worst
performance was achieved when using Dlongest-C. Differences
Table 1 Overview of nodule management scoring system categories and corresponding criteria
Scoring system Category Criteria Management
PanCan 1 Normal finding, nodule risk index <1.5% Biennial LDCT screening
2 Low-risk of malignancy: nodule risk index 1.5% – <6% Annual LDCT screening
3 Moderate risk of malignancy: nodule risk index 6% – <30% 3-month LDCT
4 High-risk of malignancy: nodule risk index ≥30% Direct referral
Lung-RADS (version 1.0) 1 No nodules, or nodules with complete, central, popcorn, or concentric
rings of calcification, fat containing nodules
Annual LDCT screening
2 Solid nodules < 6 mm
Part-solid nodules <6 mm in total diameter
Pure ground-glass nodules <20 mm
Annual LDCT screening
3 Solid nodules ≥ 6 – <8 mm
Part-solid nodules ≥ 6 mm in total diameter with solid component
< 6 mm
Pure ground-glass nodules ≥20 mm
6-month LDCT
4A Solid nodules ≥ 8 – < 15 mm
Part-solid nodules ≥6 mm with solid component ≥6 – <8 mm
3-month LDCT; PET/CT
4B Solid nodules ≥ 15 mm
Part-solid nodules with a solid component ≥ 8 mm
Chest CTwith/without contrast,
PET/CT and/or tissue sampling
NCCN (version 1.2016) 1 Solid nodule or part-solid nodule < 6 mm Annual LDCT for 2 years
2 Pure ground-glass nodule ≤ 5 mm
Multiple pure ground-glass nodules ≤ 5 mm
LDCT in 12 months
3 Pure ground-glass nodule > 5-10 mm
Multiple pure ground-glass nodules with a diameter >5 mm without
a dominant lesion
LDCT in 6 months
4 Pure ground-glass nodule > 10 mm
Multiple pure ground-glass nodules with a dominant nodule(s) with
a solid component
LDCT in 3–6 months
5 Solid nodule or part-solid nodule 6–8 mm LDCT in 3 months
6 Solid nodule or part-solid nodule > 8 mm Consider PET/CT
LDCT low-dose CT
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for the PanCan model (AUC 0.880, 0.879, 0.874) and Lung-
RADS (0.813, 0.812, 0.796) were not statistically significant.
The NCCN guidelines (0.845, 0.836 and 0.806) yielded a
statistically equivalent AUC of 0.845 when using Dmean3D,
and 0.836 using DmeanAxial. However, using Dlongest-C the
AUC was 0.806 being significantly inferior to Dmean3D (p =
0.005) and DmeanAxial (p = 0.016). See Table 4.
Impact of nodule size definition on performance
between systems
Using the DmeanAxial for all systems yielded a statistically sig-
nificant superiority of the PanCan model to Lung-RADS
(AUC 0.879 vs. 0.812; p = 0.001) and the NCCN guidelines
(0.879 vs. 0.836; p = 0.003).
Applying the Dlongest-C resulted in a substantial perfor-
mance drop of Lung-RADS (0.796) and NCCN (0.806), mak-
ing both systems significantly inferior to PanCan (0.874; both
p <0.001).
The use of Dmean3D yielded again a statistically significant
superiority of the PanCan model to Lung-RADS (0.880 vs.
0.813; p <0.001), and the NCCN guidelines (0.880 vs. 0.845;
p <0.016).
No statistically significant differences occurred between
Lung-RADS and NCCN with p = 0.507, p = 0.024 and p =
0.139, for Dlongest-C, Dmean3D and DmeanAxial, respectively.
Results are summarized in Table 3. Figures 4B, C and D
illustrate the ROC curves of the PanCan model, and category
operating points for Lung-RADS, NCCN guidelines and the
PanCan model when uniformly applying the three nodule size
definitions.
Fig. 1 Examples of nodules uniformly considered as the most suspicious
nodule per participant by all three systems. Each row depicts a nodule,
displayed in the axial (left) and coronal (right) plane and centered in the
images with a field of view of 60 x 60 mm. (A) Benign pure ground-glass
nodule, Dlongest-C 10.0 mm, Dmean3D 9.4 mm, DmeanAxial 8.8 mm, PanCan
model nodule index score of 5.5%, Lung-RADS category 2 and NCCN
category 3; (B) Benign part-solid nodule, Dlongest-C total nodule 9.4 mm
and solid component 7.2 mm, Dmean3D total nodule 8.5 mm and solid
component 6.2 mm, DmeanAxial total nodule 8.8 mm and solid component
6.0 mm, PanCan model nodule index score of 10.0%, Lung-RADS cat-
egory 4A and NCCN category 6; (C) Benign solid nodule, Dlongest-C
10.5 mm, Dmean3D 8.4 mm, DmeanAxial 9.1 mm, PanCan model nodule
index score of 4.4%, Lung-RADS category 4A and NCCN category 6.
(D) Malignant pure ground-glass nodule, Dlongest-C 12.4 mm, Dmean3D
9.8 mm, DmeanAxial 11.7 mm, PanCan model nodule index score of
8.4%, Lung-RADS category 2 and NCCN category 4; (E) Malignant
part-solid nodule, Dlongest-C total nodule 17.4 mm and solid component
7.1 mm, Dmean3D total nodule 14.7 mm and solid component 5.2 mm,
DmeanAxial total nodule 15.7 mm and solid component 6.3 mm, PanCan
model nodule index score of 22.2%, Lung-RADS category 3 and NCCN
category 6; F: Malignant solid nodule, Dlongest-C 15.2 mm, Dmean3D
13.5 mm, DmeanAxial 13.2 mm, PanCan model nodule index score of
18.1%, Lung-RADS category 4A and, NCCN category 6
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Discussion
Accurate differentiation between high-risk nodules requiring
more intense work-up and low-risk nodules is essential for the
implementation of a cost-effective lung cancer screening pro-
gramme. For decision support and standardization, various
scoring systems have been developed, all using nodule size
as the most important criterion. Nevertheless, they show dif-
ferences with respect to the use of subject demographics, nod-
ule morphological features, definitions of nodule size and cut-
off points. The purpose of this study was to assess perfor-
mance differences between the PanCan model, Lung-RADS
and the NCCN guidelines for the differentiation between ma-
lignant and benign screen-detected nodules using baseline in-
formation only.
Our results suggest that the three scoring systems indeed
show significant performance differences; the PanCan model
outperformed the NCCN guidelines and Lung-RADS. This
significant superiority of the PanCan model was seen when
applying the individual system's nodule size definitions and
when applying uniformly the same nodule size definition
(Dlongest-C, Dmean3D or DmeanAxial).
No statistically significant difference was seen between
Lung-RADS and the NCCN guidelines, either when using
the system's specific diameter definitions or when uniformly
applying any of the nodule size definitions.
All three systems showed the poorest performance when
using Dlongest-C, and the strongest performance when using the
mean diameter obtained from semi-automated volumetric
Fig. 3 Examples of nodules with variation between the longest diameter,
mean diameter based on volumetry, and mean of longest and
perpendicular diameter. Each row depicts a nodule, displayed in the
axial (left) and coronal (right) plane and centered in the images with a
field of view of 60 x 60 mm. (A) Benign solid nodule with Dlongest-C
7.8 mm, Dmean3D 5.3 mm, DmeanAxial 6.3 mm; (B) Malignant part-solid
nodule with Dlongest-C of total nodule 16.6 mm and of solid component
13.3 mm, Dmean3D of total nodule 12.3 mm and of solid component
7.4 mm, DmeanAxial of total nodule 15.0 mm and of solid component
10.6 mm; (C) Benign pure ground-glass nodule with Dlongest-C
20.6 mm, Dmean3D 13.0 mm, DmeanAxial 17.0 mm
Fig. 2 Example of one participant in which three different nodules were
considered as the risk-dominant lesion. Each row depicts a nodule,
displayed in the axial (left) and coronal (right) plane and centered in the
images with a field of view of 60 x 60 mm. (A) Solid benign nodule,
DmeanAxial 6.1 mm, risk-dominant nodule for the NCCN guidelines with
category 5; (B) Solid benign nodule, Dmean3D 8.7 mm, risk-dominant
nodule for Lung-RADS with category 4A; (C) Pure ground-glass benign
nodule, Dlongest-C 14.3 mm, risk-dominant nodule for the PanCan model
with nodule risk index of 0.14%
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segmentations (Dmean3D). This result suggests that taking the
three-dimensional information into account is superior to two
dimensions (e.g. axial measurements alone). Whether true
volumetry versus mean diameter obtained from thee-
dimensional information will result in a significant perfor-
mance difference can only be speculated. Nevertheless, we
expect that automatic or semi-automatic assessment of
volumetry will help to decrease inter-observer variability.
However, in contrast to the PanCan model and Lung-
RADS, the NCCN guidelines showed a statistically sig-
nificant susceptibility towards the definition of the nod-
ule size with a significant superiority of DmeanAxial and
Dmean3D over Dlongest-C. Dmean3D, the only diameter def-
inition using the three-dimensional extent of the nodule,
was not found to perform significantly different from
DmeanAxial for any of the three systems. This is impor-
tant because it means that diameter measurements can
be done on axial scans alone without using other pro-
jection planes.
From these results we conclude that apart from nodule size
thresholds, nodule size definition has also a significant impact
on the performance of such risk estimation systems, and
should therefore be defined and documented carefully.
In addition to nodule size and nodule type, nodule growth
is an important malignancy predictor, and the main rationale
behind the acquisition of follow-up studies [12–14]. Growth is
considered in the two categorical systems, but not in the
PanCan model that is designed for risk estimation of lesions
detected on baseline screening CTs. In order to be able to
compare the categorical strategies with the PanCan model,
we excluded this criterion. However, by doing so the poten-
tials of the two categorical systems were restricted.
We know that manual diameter measurements are prone to
substantial observer variability [15]. Using manual diameter
Table 2 Demographics of
participants and characteristics of
risk-dominant nodules
Parameter Cancers* Benign nodules * Total* P value**
Number 65 675 740
Participants 64 549 613
Age in years 61 (52–75) 58 (50–71) 58 (50–75) 0.655
Sex
Male
Female
35 (55%)
29 (45%)
292 (53%)
257 (47%)
327 (53%)
286 (47%)
0.820
Family history of lung cancer 17 (27%) 90 (16%) 107 (17%) 0.043
Emphysema 47 (73%) 367 (67%) 414 (68%) 0.287
Nodule size in mm:
Dlongest-C
Median: 13.9
16.5 (3.3–124.8)
Median: 6.1
7.6 (1.6–104.4)
8.4 (1.6–124.8) <0.001
Nodule size in mm:
Dmean3D
Median: 10.2
12.5 (2.7–84.8)
Median: 4.9
5.8 (1.3–62.3)
6.4 (1.3–84.8) <0.001
Nodule size in mm:
DmeanAxial
Median: 12.1
13.8 (2.9–95.0)
Median: 5.4
6.4 (1.2–95.5)
7.1 (1.2–95.5) <0.001
Nodule type
Solid
Part-solid
Non-solid
43 (66%)
15 (23%)
7 (11%)
590 (87%)
19 (3%)
66 (10%)
633 (85%)
34 (5%)
73 (10%)
<0.001
Perifissural 0 (0%) 55 (8%) 55 (7%) 0.017
Calcified 0 (0%) 96 (14%) 96 (13%) 0.001
Nodule count 0.3 (0–4) 0.5 (0–5) 0.5 (0–5) 0.017
Nodule location
Upper lobe
38 (58%) 327 (48%) 365 (49%) 0.123
Spiculation 18 (28%) 10 (1%) 28 (4%) <0.001
* Percentages or ranges are in parentheses
** P-value for benign nodules versus cancers. A p-value < 0.05 indicates a significant difference. Family history
of lung cancer pertained to parents or siblings. Presence of emphysema was dichotomous and not corresponding
to the degree of emphysema. Nodule size was measured as the longest diameter. Nodule count pertained to the
number of additional nodules in the scan. Spiculation was defined as reticular markings of tissue density with
elements of circular symmetry centered around a nodule
Dlongest-C longest diameter on axial sections, derived from computerized semi-automated segmentations,Dmean3D
mean diameter based on volumetric information, derived from computerized semi-automated segmentations,
DmeanAxial mean of longest and perpendicular diameter on axial sections, derived from computerized semi-
automated segmentations
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Fig. 4 Performances of the
PanCan model, Lung-RADS and
the NCCN guidelines are illus-
trated in ROC curves. In all fig-
ures, the PanCan model is shown
as a continuous curve based on
the continuous nodule risk index-
es and as operating points based
on the categories for nodule risk
index scores, similar to the Lung-
RADS and NCCN categories. (A)
All systems are visualized using
their own nodule size diameter
definitions, with Dlongest-C for the
PanCan model; (B) All systems
are visualized using Dlongest-C as
nodule size definition; (C) All
systems are visualized using
Dmean3D as nodule size definition;
D: All systems are visualized
using DmeanAxial as nodule size
definition
Table 3 Performance
comparisons between the PanCan
model, Lung-RADS and the
NCCN guidelines when using
different nodule size definitions
Nodule size definition PanCan Lung-RADS NCCN PanCan vs.
Lung-RADS
PanCan vs.
NCCN
Lung-RADS
vs. NCCN
Nodule size definition
as published
0.874 1 0.8132 0.8363 p = 0.003 p = 0.010 p = 0.175
0.869 4
Dlongest-C 0.874 0.796 0.806 p < 0.001 p < 0.001 p = 0.507
Dmean3D 0.880 0.813 0.845 p < 0.001 p = 0.016 p = 0.024
DmeanAxial 0.879 0.812 0.836 p = 0.001 p = 0.003 p = 0.139
1 Use of the longest diameter measured on axial sections derived from semi-automated volumetric segmentations
2 Use of the mean diameter based on 3D volumetric information, derived from semi-automated volumetric
segmentations
3 Use of the mean of longest and perpendicular diameter measured on axial sections derived from semi-automated
volumetric segmentations
4 Use of the longest diameter manually measured on axial sections
Dlongest-C longest diameter on axial sections, derived from computerized semi-automated segmentations,Dmean3D
mean diameter based on volumetric information, derived from computerized semi-automated segmentations,
DmeanAxial mean of longest and perpendicular diameter on axial sections, derived from computerized semi-
automated segmentations
Statistically significant differences are defined at p < 0.017, and indicated in bold
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measurements (Dlongest-M) yielded a lower performance for the
PanCan model compared to the semi-automated diameter
measurements (Dlongest-C), but the difference did not reach
significance.
In this study, the PanCan model achieved a lower perfor-
mance for nodules derived from the DLCST compared to the
validation dataset from the BCCA (0.881 vs. 0.970) [6]. This
difference is likely to be caused by different inclusion criteria
between the datasets. The PanCan study and the BCCA
dataset included smaller nodules than the DLCST, resulting
in a lower prevalence of small benign nodules in our study
(median size 5 mm, range 3–90 mm) compared to the BCCA
dataset (median size 3 mm, range 1–29 mm) [6]. Furthermore,
PFNs and calcified nodules were excluded in the PanCan
model, but were annotated in the DLCST. To account for these
design differences, both calcified and perifissural nodules
were given a nodule risk index of 0% for the PanCan model
in our study, which occurred in 151 nodules (151/740, 20%).
Another contributor to the lower performance of the PanCan
model in the current dataset is the fact that McWilliams et al.
computed the performance of the model on a nodule level.
However, we determined the performance of the PanCan
model on participant level using the risk-dominant nodules,
which introduced a selection bias towards larger benign nod-
ules that are more difficult to discriminate from malignant
lesions. We did so to more closely approximate the clinical
setting, in which a person-specific analysis is preferred over a
nodule-specific analysis.
Other nodule management systems have been published
[16, 17] that have similar categories and criteria to the models
discussed here, but differ in details. For this study, we decided
to include these three widely known systems. However, as
discussed by Baldwin [18], this does not automatically trans-
late into extensive implementation in clinical practice of these
models and guidelines.
It has to be stated that our data analysis is confined to the
performance of howwell the PanCan category 4, Lung-RADS
category 4A/4B and 1.2016 NCCN category 6 predict
malignancy and thus select nodules that require immediate
work-up or eventually will become malignant. We did not
compare how well the various follow-up algorithms perform
for nodules kept under surveillance.
Our study compares various models in a retrospective
study set-up. With more widely applied screening, there is
likely to be an increasing need for a large-scale prospective
audit taking multiple risk models into account. This should
also address the current debate whether to apply diameter
measurements or volumetry for nodule growth assessment.
Our study has limitations of which the most important one
refers to the use of ROC statistics to evaluate the performance
of clinical decision rules. As pointed out by Perandini et al.,
referring to the validation study of four prediction rules, ROC
analysis is designed to estimate the performance of a binary
classifier system and to determine an optimal threshold value
to be used as discriminator [19]. The risk estimation systems
tested in our study, however, use either a continuous scale (the
PanCan model) or multiple categorical thresholds (Lung-
RADS and NCCN) to balance a nodule's risk to represent a
malignancy and the likelihood of being benign. The different
biological behavior of fast growing aggressive and slowly
growing less aggressive malignancies further complicates
the clinical decision making. In the PanCan study, 20% of
the lung cancers did not develop from the largest (risk-
dominant) nodule [6]. Nevertheless we decided to use ROC
analysis as the most widely used method of assessing the
accuracy of a diagnostic test. In addition, by having the path-
ological standard available with 9 years of follow-up, we were
able to dichotomously divide our study nodules into benign
and malignant, and, lastly, there is to our knowledge no statis-
tical test at hand that would be more suited to evaluate the
complex multifactorial decision making of managing screen-
detected nodules.
Other limitations of our study include a relatively small
number of lung cancers (65 in total) and methodological dif-
ferences between the three scoring systems that we had to
exclude in order to compare the three systems with each other.
Table 4 Impact of nodule size
definition on performance of the
PanCan model, Lung-RADS and
the NCCN guidelines, expressed
in AUC values
Nodule size definition PanCan Lung-RADS NCCN
Dlongest-C vs. Dmean3D 0.874 vs. 0.880
p = 0.217
0.796 vs. 0.813
p = 0.190
0.806 vs. 0.845
p = 0.005
Dmean3D vs. DmeanAxial 0.880 vs. 0.879
p = 0.781
0.813 vs. 0.812
p = 0.914
0.845 vs. 0.836
p = 0.450
Dlongest-C vs. DmeanAxial 0.874 vs. 0.879
p = 0.140
0.796 vs. 0.812
p = 0.169
0.806 vs. 0.836
p = 0.016
Dlongest-C longest diameter on axial sections, derived from computerized semi-automated segmentations,Dmean3D
mean diameter based on volumetric information, derived from computerized semi-automated segmentations,
DmeanAxial mean of longest and perpendicular diameter on axial sections, derived from computerized semi-
automated segmentations
Statistically significant differences are defined at p < 0.017, and indicated in bold
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Firstly, we only considered one-time information and
disregarded information on nodule growth which is part of
Lung-RADS and the NCCN guidelines. Secondly, Lung-
RADS offers an additional category that allows radiologists
to upgrade a category 3 or 4 nodule to category 4X if visually
accessible criteria are present, making the nodule more suspi-
cious. This subjective procedure was disregarded in our study
[4]. These issues may have contributed to a lower perfor-
mance of Lung-RADS and the NCCN guidelines. In that re-
spect our study points to the importance of prospective eval-
uation of the clinical impact of differences in recommendation
between the PanCan model and Lung-RADS.
Furthermore, the NCCN guidelines have recently been up-
dated (version 1.2017) and harmonized with Lung-RADS.
Nevertheless, we decided to keep the results of the previous
NCCN guidelines (version 1.2016) in this study to include the
performance of a third diameter definition on risk estimation.
Lastly, the NCCN guidelines included separate rules for mul-
tiple pure ground-glass nodules, based on their size and the
presence of a dominant lesion. However, there is no clear
definition of the dominant lesion, and up to now it has not
been shown that the presence of multiple pure ground-glass
nodules represents an increased risk factor [20]. Therefore, the
presence of multiple (pure ground-glass) nodules was not tak-
en as a separate risk factor in our study.
In conclusion, the PanCan model performs significantly
better than Lung-RADS and the 1.2016 NCCN guidelines
for differentiation between malignant and benign nodules, de-
tected on baseline screening CT and without taking nodule
growth into account. Different nodule size definitions have
an impact on the performance of the three systems, with sta-
tistically significant influence only for the NCCN guidelines.
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